In this newly created position, Brandon will lead manufacturing and operations at the company's 183,000 square foot Department of Defense Advanced Development and Manufacturing facility in Alachua, Florida.
Prior to joining Ology Bioservices, Brega served in various positions at Merck and Co., most recently as Associate vice president, Plant Management at the company's Durham, North Carolina location the largest vaccines-only facility in Merck's network.
Prior to joining Merck, Brega worked for a number of animal health manufacturers including Pfizer Inc., Wyeth Pharmaceuticals, Boehringer Ingelheim and Merial Ltd., leading operations and technical organizations in the production of vaccines, biologics and sterile injectables.
He has broad base of experience with both drug substance and drug product manufacturing across both small and large molecules.
Brega holds both a Bachelor of Science in Biology and Master of Arts in Management from Doane University and earned a Masters Certification in Six Sigma and Lean Six Sigma Black Belt from Villanova University.
Ology Bioservices serves both government and commercial clients, specialising in biologic drug substance manufacturing, from early stage through commercial product.
The company has 183,000 square feet of manufacturing, process development and QA/QC space in its Department of Defense Advanced Development and Manufacturing Facility in Florida.
Pfizer and Valneva report strong Phase 3 results for Lyme disease vaccine candidate
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform
Elaris FlexCo signs global licence agreement with Valneva
Sino Biological launches 2026-2027 Northern Hemisphere influenza vaccine strain antigens
Centivax Inc doses first healthy volunteers in Centi-Flu 01 Phase 1A clinical trial
Delonix Bioworks gets IND clearance for DX-104 in China
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
European Commission approves GSK's Arexvy for adults aged 18 and over